GCP
GSA Capital Partners Portfolio holdings
AUM
$1.43B
1-Year Return
20.34%
This Quarter Return
+12.71%
1 Year Return
+20.34%
3 Year Return
+63.52%
5 Year Return
+120%
10 Year Return
+237.47%
AUM
$1.43B
AUM Growth
+$322M
(+29%)
Cap. Flow
+$246M
Cap. Flow
% of AUM
17.2%
Top 10 Holdings %
Top 10 Hldgs %
6.36%
Holding
2,241
New
645
Increased
572
Reduced
474
Closed
546
Top Buys
| 1 |
NVIDIA
NVDA
|
+$16M |
| 2 |
Apple
AAPL
|
+$13.6M |
| 3 |
Microsoft
MSFT
|
+$13M |
| 4 |
Berkshire Hathaway Class B
BRK.B
|
+$8.08M |
| 5 |
JPMorgan Chase
JPM
|
+$7.42M |
Top Sells
| 1 |
CSX Corp
CSX
|
+$4.47M |
| 2 |
Blackstone
BX
|
+$4.34M |
| 3 |
WK Kellogg Co
KLG
|
+$3.21M |
| 4 |
Cal-Maine
CALM
|
+$2.92M |
| 5 |
nVent Electric
NVT
|
+$2.69M |
Sector Composition
| 1 | Technology | 18.52% |
| 2 | Financials | 15.35% |
| 3 | Healthcare | 14.19% |
| 4 | Industrials | 11.58% |
| 5 | Consumer Discretionary | 11.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1676
SCYNEXIS
SCYX
$43.6M
| $36K | ﹤0.01% |
+53,507
| New | +$36K |
|
1677
ALX Oncology
ALXO
$62.7M
| $34K | ﹤0.01% |
+81,326
| New | +$34K |
|
1678
Berry Corp
BRY
$251M
| $33K | ﹤0.01% |
11,895
-131,417
| -92% | -$365K |
|
|
WDH
1679
Waterdrop
WDH
$676M
| $33K | ﹤0.01% |
+24,112
| New | +$33K |
|
1680
cbdMD
YCBD
$6.08M
| $33K | ﹤0.01% |
37,465
+33,495
| +844% | +$29.5K |
|
1681
Smart Sand
SND
$75.1M
| $32K | ﹤0.01% |
15,931
+2,947
| +23% | +$5.92K |
|
1682
TrueCar
TRUE
$172M
| $32K | ﹤0.01% |
16,778
-88,092
| -84% | -$168K |
|
1683
GrafTech
EAF
$199M
| $29K | ﹤0.01% |
2,983
+1,767
| +145% | +$17.2K |
|
1684
Advantage Solutions
ADV
$600M
| $28K | ﹤0.01% |
+20,882
| New | +$28K |
|
1685
Heritage Global
HGBL
$65.7M
| $24K | ﹤0.01% |
+10,802
| New | +$24K |
|
1686
Gain Therapeutics
GANX
$62.2M
| $23K | ﹤0.01% |
+12,756
| New | +$23K |
|
|
VXRT
1687
DELISTED
Vaxart
VXRT
| $22K | ﹤0.01% |
+48,548
| New | +$22K |
|
|
BORR
1688
Borr Drilling
BORR
$884M
| $22K | ﹤0.01% |
12,229
-103,964
| -89% | -$187K |
|
1689
VYNE Therapeutics
VYNE
$7.82M
| $22K | ﹤0.01% |
+13,466
| New | +$22K |
|
1690
Glimpse Group
VRAR
$31M
| $20K | ﹤0.01% |
14,956
| – | – |
|
1691
Rockwell Medical
RMTI
$56.8M
| $19K | ﹤0.01% |
+22,306
| New | +$19K |
|
1692
C4 Therapeutics
CCCC
$188M
| $16K | ﹤0.01% |
10,963
-32,978
| -75% | -$48.1K |
|
1693
Pliant Therapeutics
PLRX
$104M
| $16K | ﹤0.01% |
14,142
-20,530
| -59% | -$23.2K |
|
1694
Rani Therapeutics
RANI
$23.3M
| $13K | ﹤0.01% |
25,391
-19,242
| -43% | -$9.85K |
|
|
BKYI
1695
BIO-key International
BKYI
$5.21M
| $11K | ﹤0.01% |
+13,314
| New | +$11K |
|
1696
N-able
NABL
$1.53B
| – | – |
-14,869
| Closed | -$105K |
|
1697
NewAmsterdam Pharma
NAMS
$3.03B
| – | – |
-22,358
| Closed | -$458K |
|
1698
Neurocrine Biosciences
NBIX
$14B
| – | – |
-2,667
| Closed | -$295K |
|
1699
NBT Bancorp
NBTB
$2.26B
| – | – |
-10,302
| Closed | -$442K |
|
1700
Nuveen Churchill Direct Lending
NCDL
$772M
| – | – |
-25,798
| Closed | -$438K |
|